Meeder Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Meeder Asset Management’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,074	Closed	-$4K	–	1893
2018 Q3	$4K	Buy	1,074 +116	+12%	+$418	﹤0.01%	1388
2018 Q2	$3.6K	Buy	958 +760	+384%	+$3.7K	﹤0.01%	1326
2018 Q1	$1K	Buy	+198	New	+$922	﹤0.01%	1526
2017 Q2	–	Sell	-847	Closed	-$5K	–	2045
2017 Q1	$5K	Buy	+847	New	+$4.64K	﹤0.01%	1127

Meeder Asset Management's KERX Position: Q4 2018 in Review

Meeder Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 1,074 shares — an estimated $4K sold.

Meeder Asset Management first reported a position in KERX in Q1 2017 and held it in 4 quarters. The position peaked at $5K in Q1 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

Meeder Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
Meeder Asset Management sold 1,074 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $4K.
Meeder Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q1 2017 and held it in 4 quarters.
Meeder Asset Management's Keryx Biopharmaceuticals Inc position peaked at $5K in Q1 2017.
1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on Meeder Asset Management's 13F filing for Q4 2018, filed 17 Jan 2019.